J&J angles Darzalex for first move into early-stage myeloma with trial win, FDA filing

After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood disorder.